Skip to main content Accessibility help
×
×
Home
  • Print publication year: 2014
  • Online publication date: October 2014

Chapter 19 - Non-Parkinson’s disease tremor

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Imaging Acute Neurologic Disease
  • Online ISBN: 9781139565653
  • Book DOI: https://doi.org/10.1017/CBO9781139565653
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

1. DemirkiranM, BozdemirH, SaricaY (2001). Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand 104: 63–67.
2. ZijlmansJC, ThijssenHO, VogelsOJ, et al. (1995). MRI in patients with suspected vascular parkinsonism. Neurology 45: 2183–2188.
3. TzenKY, LuCS, YenTC, et al. (2001). Differential diagnosis of Parkinson’s disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 42: 408–413.
4. GerschlagerW, BencsitsG, PirkerW, et al. (2002). [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord 17: 518–523.
5. ZijlmansJ, EvansA, FontesF, et al. (2007). [(123)I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord 22: 1278–1285.
6. UbhiK, LowP, MasliahE (2011). Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 34: 581–590.
7. StefanovaN, BückeP, DuerrS, et al. (2009). Multiple system atrophy: an update. Lancet Neurol. 8: 1172–1178.
8. BensimonG, LudolphA, AgidY, et al.( 2009). NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132: 156–171.
9. Jecmenica-LukicM, PoeweW, TolosaE, et al. (2012). Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 11: 361–368.
10. WilliamsDR, LeesAJ (2009). Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8: 270–279.
11. ArmstrongMJ, LitvanI, LangAE, et al. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology 80: 496–503.
12. LudolphAC, KassubekJ, LandwehrmeyerBG, et al. (2009). Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatmentoptions. Eur J Neurol 16: 297–309.
13. SeppiK (2007). MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. Parkinsonism Relat Disord. 13 (suppl 3): S400–405.
14. RollandY, VérinM, PayanCA, et al. (2011). NNIPPS Study Group. A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability. J Neurol Neurosurg Psychiatry 82: 1025–1032.
15. JesseS, KassubekJ, MüllerHP, LudolphAC, UnrathA (2012). Signal alterations of the basal ganglia in the differential diagnosis of Parkinson’s disease: a retrospective case-controlled MRI data bank analysis. BMC Neurol 12: 163.
16. FockeNK, HelmsG, PantelPM, et al. (2011). Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging. AJNR 32: 2087–2092.
17. FockeN, HelmsG, ScheeweS, et al. (2011). Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp 32: 1905–1915.
18. WangY, ButrosSR, ShuaiX, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR 2012; 33: 266–273.]
19. LeeSE, RabinoviciGD, MayoMC, et al. (2011). Clinicopathological correlations in corticobasal degeneration. Ann Neurol 70: 327–340.
20. BoelmansK, BodammerNC, SuchorskaB, et al. (2010). Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson’s disease. Parkinsonism Relat Disord 16: 498–502.
21. VarroneA, InnisRB, MarekK, et al. (1998). Evaluation of patients with parkinsonism with [123]IBF and b-CIT SPECT. J Nucl Med 39: 14.
22. PirkerW, AsenbaumS, BencsitsG, et al. (2000). [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15: 1158–1167.
23. AntoniniA, BentiR, De NotarisR, et al. (2003). 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 24: 149–150.
24. PlotkinM, AmthauerH, KlaffkeS, et al. (. 2005). Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112: 677–692.
25. LarischR, KlimkeA (1998). On the clinical impact of cerebral dopamine D2 receptor scintigraphy. Nuklearmedizin 37: 245–250.
26. EckertT, BarnesA, DhawanV, et al. (2005). FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 26: 912–921.
27. SawleGV, BrooksDJ, MarsdenCD, et al. (1991). Corticobasal degeneration: a unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 114: 541–556.
28. TregliaG, StefanelliA, CasonE, et al. (2011). Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson’s disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 113: 823–829.
29. HolmesG (1904). On certain tremors in organic cerebral lesions. Brain 27: 325–375.
30. PaviourDC, JägerHR, WilkinsonL, et al. (2006). Holmes tremor: application of modern neuroimaging technique. Mov Disord 21: 2260–2662.
31. RiederCR, RebouçasRG, FerreiraMP (2003). Holmes tremor in association with bilateral hypertrophic olivary degeneration and palatal tremor: chronological considerations. Case report. ArqNeuropsiquiatr 61: 473–477.
32. RemyP, de RecondoA, DeferG, et al. (1995). Peduncular rubral tremor and dopaminergic denervation: a PET study. Neurology 45: 472–477.
33. GajosA, BoguckiA, SchinwelskiM, et al. (2010). The clinical and neuroimaging studies in Holmes tremor. Acta Neurol Scand 122: 360–366.
34. MatsuoF, AjaxET (1979). Palatal myoclonus, and denervation supersensitivity in the central nervous system. Ann Neurol 5: 72–88.
35. GoyalM, VersnickE, TuiteP, et al. (2000). Hypertrophic olivary degeneration: metaanalysis of the temporal evolution of MR findings. AJNR 21: 1073–1077.
36. HallerS, WinklerDT, GobbiC, et al. (2006). Prominent activation of the putamen during essential palatal tremor: a functional MR imaging case study. AJNR 27: 1272–1274.
37. NitschkeMF, KrugerG, BruhnH, et al. (2001). Voluntary palatal tremor is associated with hyperactivation of the inferior olive: a functional magnetic resonance imaging study. Mov Disord 16: 1193–1195.
38. LouisED, OkunMS (2011). It is time to remove the “benign” from the essential tremor label. Parkinsonism Relat Disord 17: 516–520.
39. NicolettiG, MannersD, NovellinoF, et al. (2010). Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. Neurology 74: 988–994.
40. BudisicM, TrkanjecZ, BosnjakJ, et al. (2009). Distinguishing Parkinson’s disease and essential tremor with transcranial sonography. Acta Neurol Scand 119: 17–21.
41. DanielsC, PellerM, WolffS, et al. (2006). Voxel-based morphometry shows no decreases in cerebellar gray matter volume in essential tremor. Neurology 67: 1452–1456.
42. BenamerTS, PattersonJ, GrossetDG, et al. (2000). Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15: 503–510
43. AntoniniA, IsaiasIU, CiliaR, et al. (2005). Striatal dopamine transporter (DAT) abnormalities in patients with sporadic and familial essential tremor (ET): a comparative study with (123I)ioflupane-SPECT. Mov Disord 20: S172.
44. SchwartzM, GrosharD, InzelbergR, et al. (2004). Dopamine transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Relat Disord 10: 385–389.
45. IsaiasIU, BentiR, CiliaR, et al. (2007). [123I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor vs. akinetic–rigid onset. Neuroreport 18: 1499–1502.
46. IsaiasIU, MarottaG, HiranoS, et al. (2010). Imaging essential tremor. Mov Disord 25: 679–686.
47. Sixel-DöringF, LiepeK, MollenhauerB, et al. (2011). The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258: 2147–2154.
48. SchneiderSA, EdwardsMJ, MirP, et al. (2007). Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 22: 2210–2215.
49. ApartisE, TisonF, ArneP, et al. (2001). Fast orthostatic tremor in Parkinson’s disease mimicking primary orthostatic tremor. Mov Disord 16: 1133–1136
50. GerschlagerW, MunchauA, KatzenschlagerR, et al. (2004). Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord 19: 788–795.
51. TrocelloJM, Zanotti-FregonaraP, RozeE, et al. (2008). Dopaminergic deficit is not the rule in orthostatic tremor. Mov Disord 23: 1733–1738.
52. KatzenschlagerR, CostaD, GerschlagerW, et al. (2003). [123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. Ann Neurol 53: 489–496.
53. AdamsJS, AdamsPE, NguyenD, et al. (2007). Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 69: 851–859.
54. CeravoloR, AntoniniA, VolterraniD, et al. (2005). Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology 65: 1971–3.
55. ScaglioneC, GinestroniA, VellaA, et al. (2008). MRI and SPECT of midbrain and striatal degeneration in fragile X-associated tremor/ataxia syndrome. J Neurol 255: 144–146.
56. MascalchiM, VellaA, CeravoloR (2012). Movement disorders: role of imaging in diagnosis. J Magn Reson Imaging 35: 239–256
57. SinhaS, TalyAB, RavishankarS, et al. (2006). Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology 48: 613–621.
58. KishibayashiJ, SegawaF, KamadaK, et al. (1993). Study of diffusion weighted magnetic resonance imaging in Wilson’s disease [in Japanese]. Rinsho Shinkeigaku 33: 1086–1089.
59. AlginO, TaskapiliogluO, HakyemezB, et al. (2010). Structural and neurochemical evaluation of the brain and pons in patients with Wilson’s disease. Jpn J Radiol 28: 663–671.
60. TarnackaB, SzeszkowskiW, GolebiowskiM, et al. (2008). MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov Disord 23: 1560–1566.
61. BarthelH, HermannW, KlugeR, et al. (2003). Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR 24: 234–238.
62. JeonB, KimJ, JeongJM, et al. (1998). Dopamine transporter imaging with [123I]-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J Neurol Neurosurg Psych 65: 60–64.
63. HinsonVK, CuboE, ComellaC, et al. (2005). Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord 20: 1592–1597.
64. LangAE, KollerWC, FahnS (1995). Psychogenic Parkinsonism. Arch Neurol 52: 802–810.
65. GaigC, MartiMJ, TolosaE, et al. (2006). 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord 21: 1994–1998.
66. Hassin-BaerS, SirotaP, KorczynAD, et al. (2001). Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108: 1299–1308.
67. TinazziM, OttavianiS, IsaiasIU, et al. (2008). [123I] FP-CIT SPET imaging in drug induced parkinsonism. Mov Disord 23: 1825–1829.
68. TinazziM, AntoniniA, BoviTT, et al. (2009). Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 256: 910–915.
69. BurnDJ, BrooksDJ (1993). Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 43: 552–556.
70. TinazziM, CiprianiA, MatinellaA, et al. (2012). [123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophr Res 139: 40–45.
71. RobottomBJ, WeinerWJ, FactorSA (2011). Movement disorders emergencies. Part 1: hypokinetic disorders. Arch Neurol 68: 567–572.